Abstract
EGFR, which plays a vital role as a regulator of cell growth, is one of the intensely studied TK targets of anticancer inhibitors. The most two common anticancer inhibitors are anilinoquiazolines and anilinoquinolines that inhibit EGFR kinase intracellularly. The present investigation dealt with design (pharmacophore, docking and binding energy) and synthesis of a new series of 4-anilinoquinoline-3-carboxamide derivatives as potential anticancer agents targeting EGFR. All the newly synthesized compounds were screened for their anticancer activity against MCF-7 and compounds 4f, 7a and 7b showed significant activity with IC50 values 13.96 μM, 2.16 μM and 3.46 μM, respectively. Most of the synthesized compounds were subjected to enzyme assay (EGFR TK) for measuring their inhibitory activity with the determination of IC50 values and the preliminary results revealed that compound 7b, which had potent inhibitory activity in tumor growth and had potent activity on the EGFR TK enzyme with 67% inhibition compared to ATP would be a potential anticancer agent.
The present work explores the utility of 4-anilino quinolone-3-carboxamide, a privileged scaffold as inhibitors of protein kinases (EGFR) with high and selective anticancer activities. [Display omitted]
•We use computer aided drug design to discover site-specific inhibitors for EGFR.•The proposed compounds were selecting due to their fit values, docking scores and binding energy.•The selected compounds were synthesized and changes in the side chains were studied to yield notable tumor activity.•The newly synthesized compounds were studies as EGFR inhibitors and as antitumor agents.